Trigger Alert: 4M Therapeutics Taps Sci-Advisor to Ignite Your Pipeline
4M just added neuroscience legend Edward Scolnick. Use this trigger to fuel deal flow, slash lead time, and hit your commission targets—pitch our screening platform now.
Published on
Do not index
Do not index
🚀 Battle Card: 4M Therapeutics Inc.
Quick trigger:
👤 Decision Maker in the News
- Edward Scolnick, M.D., Senior Scientific Advisor
💡 Why It Matters
- Bringing on a neuroscience legend fast-tracks biomarker validation and clinical credibility for bipolar disorder programs → Source
- This 4M Therapeutics Inc. sales trigger sends a clear signal: they’re doubling down on R&D differentiation.
🎯 Core Pain Point
- Limited efficacy and safety profiles in existing bipolar therapies
- Lack of validated, human-relevant biomarkers de-risking IND submissions
💰 What to Pitch
- Primary: Human neuronal cell–based screening platform → cut lead optimization time by 30%
- Expansion: Clinical biomarker qualification services → accelerate Phase I readiness
🗺️ Quick Context
- HQ: Skillman, NJ
- Employees: ≈ 50
- Rev: ≈ $5 M
- Website: [4mtx.net](https://www.4mtx.net/)
🤼 Competitive Intel
*Which other vendors you’ll probably face to win **4M Therapeutics Inc.*’s business.
- Recursion Pharmaceuticals — Phenotypic screening / AI-driven drug discovery
- Unique edge: Vast proprietary image dataset
- Evaluated by Sr. Sci. Advisor for automation & scaling
- Charles River Laboratories — Preclinical CRO services
- Unique edge: End-to-end GLP-compliant studies
- Evaluated by Dir. R&D for regulatory breadth
- Evotec — Integrated drug discovery partnerships
- Unique edge: Target-to-clinic modular platform
- Evaluated by COO for flexible collaboration
- Quanterix — Ultra-sensitive digital biomarker assays
- Unique edge: Single-molecule detection
- Evaluated by Head of Bioanalytics for precision readouts
✅ Do-Now Checklist
Connect with all decision makers on LinkedIn (links above)
Leverage the 4M Therapeutics Inc. sales trigger in your email subject line
Generate first-touch email + DM using Copy-My-Prompt (Step 7) and send today
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Never miss a 4M Therapeutics Inc. sales trigger—get daily, high-velocity intel straight to your inbox.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑ ❑
OFFER_BRIEF = ❑Human neuronal cell–based screening platform❑
PROOF_METRIC = ❑cut lead optimization time by 30%❑
CTA_STYLE = ❑quick_call❑
TONE = ❑punchy❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Edward
COMPANY = 4M Therapeutics Inc.
DEPT = R&D ≈
SIZE = ≈ 50
BOTTLENECK = ≈ limited validated biomarkers slows program advancement
EVENT = Appointment of Industry Veteran Edward Scolnick, M.D., as Senior Scientific Advisor
DETAIL = Appointment of Industry Veteran Edward Scolnick, M.D., as Senior Scientific Advisor
PAIN = limited efficacy and safety profiles in bipolar therapies
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250925580935&div=41152219
SIM_CO = Recursion Pharmaceuticals
WIN_METRIC = cut lead optimization time by 30%
NEXT_SIZE = ≈ 100
EMP_EST = ≈ 50
REV_EST = ≈ $5 M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈50-person R&D
Edward—noticed your R&D team is ≈ 50.
That’s when ≈ limited validated biomarkers slows program advancement slows growth.
We helped Recursion Pharmaceuticals fix this with Human neuronal cell–based screening platform.
Result: cut lead optimization time by 30%.
Quick call?
PS—next bottleneck hits ≈ 100.
DM ≤45 words, TONE:
Saw your post about Appointment of Industry Veteran Edward Scolnick, M.D., as Senior Scientific Advisor — limited efficacy and safety profiles in bipolar therapies.
Human neuronal cell–based screening platform. cut lead optimization time by 30%. Quick chat?